J&J Separates U.S. OTCs In "Unorthodox" Reorg To Get McNeil Back On Track
This article was originally published in The Tan Sheet
As the new head of Johnson & Johnson's beleaguered U.S. OTC business, Pat Mutchler takes on the burden of restoring the firm's reputation and manufacturing quality.
You may also be interested in...
A report by a Johnson & Johnson special committee finds organizational and middle management changes at the firm were the root causes of manufacturing and quality control lapses in the OTC drug business.
J&J names pharma vet to lead McNeil
Investment analysts are confident in Johnson & Johnson's long-term viability even though recalls of OTC drugs and the temporary closure of the facility where the products were made prompted the firm to slash full-year profits estimates and triggered a federal investigation